IL147182A0 - Diagnostics and therapeutics for diseases associated with an il-1 inflammatory haplorype - Google Patents

Diagnostics and therapeutics for diseases associated with an il-1 inflammatory haplorype

Info

Publication number
IL147182A0
IL147182A0 IL14718200A IL14718200A IL147182A0 IL 147182 A0 IL147182 A0 IL 147182A0 IL 14718200 A IL14718200 A IL 14718200A IL 14718200 A IL14718200 A IL 14718200A IL 147182 A0 IL147182 A0 IL 147182A0
Authority
IL
Israel
Prior art keywords
haplorype
therapeutics
diagnostics
inflammatory
diseases associated
Prior art date
Application number
IL14718200A
Other languages
English (en)
Original Assignee
Interleukin Genetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/345,217 external-priority patent/US6268142B1/en
Application filed by Interleukin Genetics Inc filed Critical Interleukin Genetics Inc
Publication of IL147182A0 publication Critical patent/IL147182A0/xx

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813Hybridisation assays
    • C12Q1/6827Hybridisation assays for detection of mutation or polymorphism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/156Polymorphic or mutational markers
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/172Haplotypes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Pathology (AREA)
  • Wood Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
IL14718200A 1999-06-30 2000-06-30 Diagnostics and therapeutics for diseases associated with an il-1 inflammatory haplorype IL147182A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/345,217 US6268142B1 (en) 1997-05-29 1999-06-30 Diagnostics and therapeutics for diseases associated with an IL-1 inflammatory haplotype
PCT/US2000/018318 WO2001000880A2 (en) 1999-06-30 2000-06-30 Diagnostics and therapeutics for diseases associated with an il-1 inflammatory haplotype

Publications (1)

Publication Number Publication Date
IL147182A0 true IL147182A0 (en) 2002-08-14

Family

ID=23354085

Family Applications (1)

Application Number Title Priority Date Filing Date
IL14718200A IL147182A0 (en) 1999-06-30 2000-06-30 Diagnostics and therapeutics for diseases associated with an il-1 inflammatory haplorype

Country Status (7)

Country Link
US (3) US6730476B1 (xx)
EP (1) EP1194590A2 (xx)
JP (1) JP2003508022A (xx)
AU (1) AU784224B2 (xx)
CA (1) CA2378221A1 (xx)
IL (1) IL147182A0 (xx)
WO (1) WO2001000880A2 (xx)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6720141B1 (en) * 1999-11-01 2004-04-13 Interleukin Genetics, Inc. Diagnostics and therapeutics for restenosis
WO2001000880A2 (en) * 1999-06-30 2001-01-04 Interleukin Genetics, Inc. Diagnostics and therapeutics for diseases associated with an il-1 inflammatory haplotype
US20030124524A1 (en) * 2000-06-23 2003-07-03 Kenneth Kornman Screening assays for identifying modulators of the inflammatory or immune response
CA2450809A1 (en) * 2001-06-15 2002-12-27 Interleukin Genetics, Inc. Methods for detecting and treating the early onset of aging-related conditions
US20080311581A1 (en) * 2001-11-19 2008-12-18 David Wyllie Functional polymorphisms of the interleukin-1 locus affecting transcription and susceptibility to inflammatory and infectious diseases
WO2003044176A2 (en) 2001-11-19 2003-05-30 Interleukin Genetics, Inc. Functional polymorphisms of the interleukin-1 locus affecting transcription and susceptibility to inflammatory and infectious diseases
US20070264645A1 (en) * 2002-01-25 2007-11-15 Kenneth Kornman IL-1 gene cluster and associated inflammatory polymorphisms and haplotypes
US20050064462A1 (en) * 2003-06-17 2005-03-24 Bernd Stein Methods, compositions, and kits for predicting the effect of compounds on hot flash symptoms
US20060234274A1 (en) * 2005-03-29 2006-10-19 Auckland Uniservices Limited Methods of diagnosis
EP1951903A2 (en) * 2005-10-25 2008-08-06 Interleukin Genetics, Inc. The il-1 gene cluster and associated inflammatory polymorphisms and haplotypes
EP2089538B1 (en) * 2006-11-15 2013-08-21 Interleukin Genetics, Inc. The il-1 gene cluster and insulin resistance: associated polymorphisms, haplotypes and methods of using same
US8495911B2 (en) 2007-08-31 2013-07-30 Vestas Wind Systems A/S Wind turbine siting and maintenance prediction
WO2009135219A2 (en) * 2008-05-02 2009-11-05 Interleukin Genetics, Inc. Detecting genetic predisposition to osteoarthritis associated conditions
WO2009142474A1 (en) * 2008-05-23 2009-11-26 Erasmus University Medical Center Rotterdam Genetic markers predicting age at menopause
ITMI20091054A1 (it) * 2009-06-15 2010-12-16 Istituto Ortopedico Galeazzi S P A Metodi per lo screening di polimorfismi genetici associati alla risposta immune per la valutazione della predisposizione atletica e kit relativi
US8293753B2 (en) * 2009-07-02 2012-10-23 Novartis Ag Substituted 2-carboxamide cycloamino ureas
AU2017207341A1 (en) 2016-01-12 2018-08-02 Interleukin Genetics, Inc. Methods for predicting response to treatment
US10329620B2 (en) 2017-01-12 2019-06-25 Cardioforecast Ltd. Methods and kits for treating cardiovascular disease
KR102252384B1 (ko) * 2018-10-08 2021-05-14 차의과학대학교 산학협력단 조기폐경 진단을 위한 분석방법 및 키트
US20220249660A1 (en) 2019-06-06 2022-08-11 Sitokine Limited Compositions and methods for treating lung, colorectal and breast cancer
WO2021028469A1 (en) 2019-08-12 2021-02-18 Sitokine Limited Compositions and methods for treating cytokine release syndrome and neurotoxicity
IT202000003988A1 (it) * 2020-02-26 2021-08-26 Allelica S R L Metodo per una prognosi predittiva dell’insorgenza di menopausa
WO2021205013A1 (en) 2020-04-09 2021-10-14 Sitokine Limited Compositions and methods for treating covid-19

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8311018D0 (en) 1983-04-22 1983-05-25 Amersham Int Plc Detecting mutations in dna
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
CA1284931C (en) * 1986-03-13 1991-06-18 Henry A. Erlich Process for detecting specific nucleotide variations and genetic polymorphisms present in nucleic acids
US5541308A (en) * 1986-11-24 1996-07-30 Gen-Probe Incorporated Nucleic acid probes for detection and/or quantitation of non-viral organisms
US5459039A (en) 1989-05-12 1995-10-17 Duke University Methods for mapping genetic mutations
FR2650840B1 (fr) 1989-08-11 1991-11-29 Bertin & Cie Procede rapide de detection et/ou d'identification d'une seule base sur une sequence d'acide nucleique, et ses applications
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US5547835A (en) 1993-01-07 1996-08-20 Sequenom, Inc. DNA sequencing by mass spectrometry
US5593826A (en) 1993-03-22 1997-01-14 Perkin-Elmer Corporation, Applied Biosystems, Inc. Enzymatic ligation of 3'amino-substituted oligonucleotides
US5698399A (en) * 1996-04-05 1997-12-16 Duff; Gordon W. Detecting genetic predisposition for osteoporosis
US6210877B1 (en) * 1997-03-10 2001-04-03 Interleukin Genetics, Inc. Prediction of coronary artery disease
US6720141B1 (en) * 1999-11-01 2004-04-13 Interleukin Genetics, Inc. Diagnostics and therapeutics for restenosis
GB9706359D0 (en) * 1997-03-27 1997-05-14 Gemini International Holdings Polymorphisms of an il-1 receptor antagonist gene
GB9711040D0 (en) * 1997-05-29 1997-07-23 Duff Gordon W Prediction of inflammatory disease
US6746839B1 (en) * 1998-01-12 2004-06-08 Interleukin Genetics, Inc. Diagnostics and therapeutics for an obstructive airway disease
US6635418B2 (en) * 1998-02-13 2003-10-21 Igen International, Inc. Assay methods for nucleic acid in a sample
WO2001000880A2 (en) * 1999-06-30 2001-01-04 Interleukin Genetics, Inc. Diagnostics and therapeutics for diseases associated with an il-1 inflammatory haplotype
DE60026150T2 (de) * 1999-08-30 2006-11-16 Interleukin Genetics, Inc., Waltham Diagnostika und therapeutika für osteoporose
CA2450809A1 (en) * 2001-06-15 2002-12-27 Interleukin Genetics, Inc. Methods for detecting and treating the early onset of aging-related conditions
WO2003044176A2 (en) * 2001-11-19 2003-05-30 Interleukin Genetics, Inc. Functional polymorphisms of the interleukin-1 locus affecting transcription and susceptibility to inflammatory and infectious diseases

Also Published As

Publication number Publication date
US20050064453A1 (en) 2005-03-24
WO2001000880A3 (en) 2001-11-15
US6730476B1 (en) 2004-05-04
JP2003508022A (ja) 2003-03-04
AU784224B2 (en) 2006-02-23
CA2378221A1 (en) 2001-01-04
EP1194590A2 (en) 2002-04-10
WO2001000880A2 (en) 2001-01-04
AU6067900A (en) 2001-01-31
US20090163460A1 (en) 2009-06-25

Similar Documents

Publication Publication Date Title
IL147182A0 (en) Diagnostics and therapeutics for diseases associated with an il-1 inflammatory haplorype
AU1917201A (en) Amide therapeutics and methods for treating inflammatory bowel disease
AU4176801A (en) Diagnostics and therapeutics for glaucoma
DE60015449D1 (de) Phantom für Bildgebungsvorrichtung
AU2001287272A1 (en) Genes involved in intestinal inflammatory diseases and use thereof
AU2003276220A1 (en) Diagnostics and therapeutics for diseases associated with human phosphodiesterase 2a (pde2a)
EP1111049A4 (en) NOVEL RECEPTOR PROTEIN AND METHOD FOR DIAGNOSING INFLAMMATORY DISEASES USING THE SAME
DK1065277T4 (da) Alpha-Amylasemutanter
AU2002254174A1 (en) Interferon-beta polynucleotide therapy for autoimmune and inflammatory diseases
AU2001237544A1 (en) Test and model for inflammatory disease
AU2003205627A1 (en) Diagnostics and therapeutics for diseases associated with gpr72
AU1917301A (en) Aryl nitrone therapeutics and methods for treating inflammatory bowel disease
AU2002252459A1 (en) Customized therapeutics and in situ diagnostics
DE29900026U1 (de) Doppelsitz-Schraubstock
AU2003283303A8 (en) Diagnostics and therapeutics for diseases associated with human phosphodiesterase 4b (pde4b)
GB0103514D0 (en) Test and model for inflammatory disease
AU2003206749A1 (en) Diagnostics and therapeutics for diseases associated with the gpr65 receptor
AU5472301A (en) Method to evaluate the systemic exposure in toxicological and pharmacological studies
AU2003245981A1 (en) Diagnostics and therapeutics for diseases associated with the g2a-receptor (g2a)
GB0004313D0 (en) Test and model for inflammatory disease
IL146653A0 (en) Diagnostics and therapeutics for restenosis
DE29906745U1 (de) Sitzmöbel
ATA90082000A (de) Sitzmöbel
GB0007958D0 (en) Foldaway tiered seating
TW563528U (en) Chair with toilet facility